Cellectar Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CLRB Nasdaq 2836 www.cellectar.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cellectar Biosciences, Inc.

Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... - May 14th, 2026 5:02 pm
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - May 14th, 2026 3:08 pm
Cellectar (CLRB) Q1 2026 Earnings Transcript - May 14th, 2026 12:49 pm
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - May 14th, 2026 5:15 am
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 - May 11th, 2026 6:05 am
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know - May 7th, 2026 10:00 am
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia - May 5th, 2026 8:21 am
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia - May 5th, 2026 5:10 am
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million - May 5th, 2026 5:00 am
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 - Apr 21st, 2026 8:00 am
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - Apr 14th, 2026 6:35 am
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Mar 4th, 2026 10:32 am
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - Mar 4th, 2026 7:59 am
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Mar 4th, 2026 5:15 am
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Feb 25th, 2026 6:05 am
Cellectar Biosciences Expands Global Intellectual Property Estate - Feb 17th, 2026 6:05 am
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - Jan 9th, 2026 6:05 am
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies - Dec 16th, 2025 6:05 am
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Nov 13th, 2025 2:00 pm
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 5:20 am